Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease
Inflammatory Bowel Diseases · 01.02.2026 · 32 (2) · 390-393
DOI: 10.1093/ibd/izaf255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 10.11.2025. Verfasst von Suzanne I Anjie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Netherlands. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Prometheus Laboratories to AmsterdamUMC.
Abstract (Originalsprache)
Lay Summary Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn’s disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
- Az Delta, Department of Gastroenterology, Roeselare, Belgium.
- Imelda General Hospital, Bonheiden, Belgium.
- Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands.
- Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.
- Department of Internal Medicine, University of Szeged, Szeged, Hungary.
ORCID-Profile: Suzanne I Anjie, Peter Bossuyt, Séverine Vermeire
Förderung
- Prometheus Laboratories to AmsterdamUMC
Zitieren
APA
Anjie, S. I., D'Haens, G. R., Baert, F., Bossuyt, P., Hoentjen, F., Clasquin, E., Molnár, T., Löwenberg, M., Vermeire, S., Panetta, J. C., & Dervieux, T. (2026). Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease. Inflammatory Bowel Diseases, 32(2), 390-393. https://doi.org/10.1093/ibd/izaf255
Vancouver
Anjie SI, D'Haens GR, Baert F, Bossuyt P, Hoentjen F, Clasquin E, et al. Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease. Inflammatory Bowel Diseases. 2026;32(2):390-393. doi:10.1093/ibd/izaf255
BibTeX
@article{Anjie2026,
author = {Anjie, Suzanne I and D'Haens, Geert R and Baert, Filip and Bossuyt, Peter and Hoentjen, Frank and Clasquin, Esmé and Molnár, Tamás and Löwenberg, Mark and Vermeire, Séverine and Panetta, J Carl and Dervieux, Thierry},
title = {Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {2},
pages = {390--393},
doi = {10.1093/ibd/izaf255}
}
EUVIMED